Loss-of-function alterations in STAG2 were associated with poor outcomes in the landmark Ewing sarcoma genomic landscape studies, and in some cases loss of STAG2 expression was identified without a known mutation [1–3]. This evidence concerns the gene STAG2 and Ewing sarcoma.